Status of drug-eluting coronary stents.
Significant advances in interventional cardiology have occurred over the past 30 years, leading to substantial increases in the number and anatomic complexity of treated patients, the long-term success of these procedures, and a reduction in the need for coronary bypass surgery. While the risk ofrestenosis has been dramatically reduced by drug-eluting stents, delayed neo-intimal healing has led to a small, but significant occurrence of "late" stent thrombosis. This thrombotic risk is substantially reduced by continuation of dual-anti-platelet therapy for one or more years following DES placement. Current guidelines for patient selection for DES, for duration of DAT following DES, and for facing surgical and invasive procedures after DES were discussed, and the avoidance of early discontinuation of anti-platelet therapy following DES was emphasized.
Chodosh
Adam
A
clinical Cardiology Program, Rhode Island Hospital, USA. achodosh@lifespan.org
Korr
Kenneth S
KS
Burtt
Douglas
D
D015906:Angioplasty, Balloon, Coronary; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D032921:Consensus; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000628:therapy; D023903:Coronary Restenosis / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D054855:Drug-Eluting Stents; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017239:Paclitaxel / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; C446540:thienopyridine; D017239:Paclitaxel; D001241:Aspirin; D020123:Sirolimus